|
Symphogen is a biotechnology company located in Copenhagen, Denmark that produces recombinant polyclonal antibody drugs for disease treatment and prevention. Their three main areas of therapeutic research are immunoglobulin replacement, cancer, and infectious diseases. The company was founded in 2000 and has patents on a drug discovery platform called Symplex and a drug manufacturing platform called Sympress. Currently, ten drugs are being developed with rozrolimupab (Sym001) being the lead product.〔Symphogen. Copenhagen2008 (2009 15 April 2009 ); Available from: http://www.symphogen.com/web/guest.〕 ==Partner Collaborations== Genentech, Inc.: Collaboration pact with Genentech which enables both companies to utilize Symplex technology to help discover new antibodies against three undisclosed infectious disease targets. Meiji Seika Kaisha, Ltd: Sym006 development and license agreement with Meiji Seika that establishes a collaboration of research, development, and commercialization. Biovitrum: A co-development and commercialization agreement with Biovitrum for Sym001. The United States Food and Drug Administration granted an orphan drug designation to Sym001. NIAID/NIH: Sym002 developmental grant with the National Institutes of Health for a recombinant polyclonal antibody against smallpox. The grant enables Symphogen to complete pre-clinical development of Sym002, which allows submission of an Investigational New Drug application for new safety studies. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Symphogen」の詳細全文を読む スポンサード リンク
|